Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Baxter International

Thumbnail
September 03, 2020

Medtechs that book the most sales per employee face the greatest losses

Welcome to the calm before the Covid-19 storm.

Thumbnail
August 05, 2020

Philips spends big in-house while Becton favours buying

The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.

Article image
Vantage logo
July 09, 2020

Medical device mergers on pause

2019 was an average year for medtech M&A. 2020, not so much.

Article image
Vantage logo
August 22, 2019

The extremes converge in big medtech’s hiring practices

Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.

Article image
Vantage logo
May 31, 2019

MD Start bucks the trend for later-stage medtech investing

Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.

Article image
Vantage logo
August 02, 2018

Medtechs prioritise efficiency when it comes to hiring

Big cap medtech is hiring, largely thanks to organic growth.

Vantage logo
May 02, 2018

Medtech in 2024: six years of stability, or as wild as the past?

Vantage logo
October 17, 2017

How do you solve a problem like Maria?

Article image
Vantage logo
July 04, 2017

Startling reversal of fortunes as large-cap medtechs soar

Vantage logo
June 29, 2017

Interview – Baxter aims to entrench leadership in peritoneal dialysis

Vantage logo
October 26, 2016

Mega float could push Convatec towards profit

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.